US FDA shuffles senior drug centre staff
This article was originally published in SRA
Executive Summary
There is wide speculation that personnel changes within the upper echelons of the US Food and Drug Administration’s Center for Drug Evaluation and Research could have a significant impact on the regulation of pharmaceutical companies, particularly in the area of promotion and advertising.